Business
Spruce Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates
SOUTH SAN FRANCISCO, Calif., May 06, 2025--Spruce Biosciences, Inc. (OTC: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today reported financial results for the first quarter ended March 31, 2025 and provided corporate updates.
About this update from Spruce Biosciences, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/48676009102e14044ba3d8648bb35c3c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/nBNIX1rQ_XotMdtaamW_Fg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/48676009102e14044ba3d8648bb35c3c","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/x_2IOhJhd_J_FxT7PwDAYg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/48676009102e14044ba3d8648bb35c3c","width":1024,"height":512}},"lazy":false},{"type":"text","content":"Acquisition of Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)","length":128,"tagName":"p","attribs":{}},{"type":"text","content":"Biologics License Application (BLA) Submission to U.S. FDA for TA-ERT Expected in 1H 2026","length":89,"tagName":"p","attribs":{}},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., May 06, 2025--(BUSINESS WIRE)--Spruce Biosciences, Inc. (OTC: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today reported financial results for the first quarter ended March 31, 2025 and provided corporate updates.","length":366,"tagName":"p"},{"type":"text","content":""With no FDA-approved treatments currently available to treat MPS IIIB, TA-ERT has the potential to be a groundbreaking advancement for patients and families impacted by this devastating disease," said Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer of Spruce. "Across the landscape, this is an incredibly important and exciting time for patients and families affected by neuropathic MPS diseases. Looking ahead, we remain focused on pursuing accelerated approval of TA-ERT and filing the BLA in the first half of 2026. We also plan to initiate a confirmatory study prior to potential accelerated approval of TA-ERT and enable expanded access programs to ensure that patients have access to therapy."","length":729,"tagName":"p"},{"type":"text","content":"Corporate Updates","length":17,"tagName":"p"},{"type":"list","ite...